Literature DB >> 10213433

Effects of two calculated plasma sufentanil concentrations on the hemodynamic and bispectral index responses to Mayfield head holder application.

P Hans1, J F Brichant, P Y Dewandre, J D Born, M Lamy.   

Abstract

The effects of two calculated plasma sufentanil (SUF) concentrations on the hemodynamic and bispectral index (BIS) responses to Mayfield head holder (MH) application were studied in 20 patients scheduled for intracranial surgery. Premedication consisted of hydroxyzine, alprazolam, and atropine given orally 1 hour before surgery. Anesthesia was provided with propofol (PPF) and SUF using a target-controlled infusion device. Patients were randomly assigned to one of two groups according to calculated plasma concentrations: 3 microg/mL(-1) of PPF and 0.5 ng/mL(-1) of SUF in group I (GI) and 3 microg/mL(-1) of PPF and 1 ng/mL(-1) of SUF in group II (GII). The MH was fixed 33.0+/-6.6 minutes (mean +/- SD) after induction. Systolic (SAP), diastolic (DAP), and mean arterial pressure (MAP) as well as heart rate (HR) and BIS were recorded 1 minute before pinning (baseline) as well as 1 minute (P1), 2 minutes (P2), and 3 minutes (P3) after pinning. Multivariate repeat-measured analyses of variance were applied to the baseline-subtracted measurements of hemodynamic and BIS values. Groups were compared using the Student's t test, and P < .05 was considered to be statistically significant. Patients' characteristics, baseline hemodynamic values, and BIS values were similar in both groups. A significant overall time effect was observed for all variables, but no significant overall SUF effect was detected. Increases in SAP, MAP, DAP, and HR did not differ significantly between groups. The increase in hemodynamic variables did not exceed 20% of baseline value in either group. In contrast, at P1, the increase in BIS over the baseline value was significantly higher in GI (15.0+/-7.9) than in GII (6.7+/-6.5). In conclusion, MH application was associated with a significant, although not clinically relevant, increase in hemodynamic variables whatever the calculated plasma SUF concentration (0.5 or 1.0 ng/mL(-1)). In contrast, the increase in BIS observed at pinning was significantly higher in patients with the lowest calculated plasma SUF concentrations. This suggests that the BIS response to noxious stimulation is modulated by the analgesic regimen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213433     DOI: 10.1097/00008506-199904000-00002

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  4 in total

1.  Hemodynamic and bispectral index changes following skull pin attachment with and without local anesthetic infiltration of the scalp.

Authors:  Parmod Kumar Bithal; Mihir Prakash Pandia; Rajender Singh Chouhan; Deepak Sharma; Hemant Bhagat; Hari Hara Dash; Rajni Arora
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

2.  How effective is the local anesthetic infiltration of pin sites prior to application of head clamps: A prospective observational cohort study of hemodynamic response in patients undergoing elective craniotomy.

Authors:  Ayesha Arshad; Muhammad Shahzad Shamim; Muhammad Waqas; Hina Enam; Syed Ather Enam
Journal:  Surg Neurol Int       Date:  2013-07-18

3.  Analgesia nociception index and hemodynamic changes during skull pin application for supratentorial craniotomies in patients receiving scalp block versus pin-site infiltration: A randomized controlled trial.

Authors:  Kaushic A Theerth; Kamath Sriganesh; Dhritiman Chakrabarti; K R Madhusudan Reddy; G S Umamaheswara Rao
Journal:  Saudi J Anaesth       Date:  2019 Oct-Dec

4.  Comparison of intravenous labetalol and bupivacaine scalp block on the hemodynamic and entropy changes following skull pin application: A randomized, open label clinical trial.

Authors:  Sidhesh Bharne; Prasanna Udupi Bidkar; Ashok Shankar Badhe; Satyen Parida; Andi Sadayandi Ramesh
Journal:  Asian J Neurosurg       Date:  2016 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.